Massachusetts-based nference has raised USD 60 million in Series C funding led by Matrix Capital Management, with participation from Matrix Partners, Mayo Clinic Ventures, and NTTVC.
nference intends to use the proceeds to advance the development of software and learning models on its nferX software platform, enabling novel diagnostics and therapeutics.
Founded in 2013, nference operates a biomedical knowledge synthesis platform that captures and analyzes health data, including unstructured information to help researchers in drug discovery. Its AI-powered platform uses neural networks (shallow and deep learning models) for the automatic extraction of insights from clinical notes, scientific literature, pathology images, ECG waveforms, and genomic sequences.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.